Drugs / RC108
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04617314 | Mar 2021 → Dec 2025 | cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05821933 | Sep 2023 → Sep 2025 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06962865 | Jun 2025 → May 2026 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05628857 | Nov 2022 → Dec 2025 | digestive system cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | RemeGen Co., Ltd. | Results 2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer remegen.com ↗
At the 2025 ASCO Annual Meeting, RemeGen presented data from phase 1b/2 clinical trial of RC108 in combination with furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on EGFR-TKI treatment, and the results showed obvious synergistic effect between RC108 and furmonertinib. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | RemeGen Co., Ltd. | 2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer remegen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05821933 ↗ |
| Known as | RC108 for injection | “RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.” NCT04617314 ↗ |
| Modality | Other / unclassified | “RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder” NCT05628857 ↗ |
| Route | Intravenous | “intravenous administration” NCT05628857 ↗ |